Expertise in
12
conditions

Dr. Fabio Cappuccini

Gynecologic Oncology | Obstetrics and Gynecology
101 The City Dr S, Building 29, Suite 501, 
Orange, CA 
Expertise in
12
conditions
101 The City Dr S, Building 29, Suite 501, 
Orange, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Fabio Cappuccini is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Orange, California. Dr. Cappuccini is highly rated in 12 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Bladder Reconstruction, and Hernia Surgery.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Associates
  • MEDICARE MAPD

Locations

101 The City Dr S, Building 29, Suite 501, Orange, CA 92868

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Enrollment Status: Terminated
Publish Date: September 10, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy
Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy
Enrollment Status: Unknown
Publish Date: April 25, 2022
Intervention Type: Biological
Study Drugs: AVOVA-1, MC
Study Phase: Phase 2
View 2 Less Clinical Trials

3 Total Publications

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 17, 2022
Similar Doctors
Expertise in
20
conditions
Dr. Robert E. Bristow
Gynecologic Oncology | Oncology | Rheumatology
Expertise in
20
conditions
Dr. Robert E. Bristow
Gynecologic Oncology | Oncology | Rheumatology

Regents Of The University Of California

101 The City Dr S, 
Orange, CA 
 (0.1 miles away)
714-456-7002
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Bristow is a Gynecologic Oncologist and an Oncologist in Orange, California. Dr. Bristow is highly rated in 20 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Oophorectomy, and Hysterectomy.

Expertise in
11
conditions
Dr. Beth Y. Karlan
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Expertise in
11
conditions
Dr. Beth Y. Karlan
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

The Regents Of The University Of California

200 Medical Plaza, 
Los Angeles, CA 
 (37.2 miles away)
310-794-7274
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Beth Karlan is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Los Angeles, California. Dr. Karlan is highly rated in 11 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Oophorectomy, and Salpingo-Oophorectomy.

Expertise in
18
conditions
Dr. Dana M. Chase
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
18
conditions
Dr. Dana M. Chase
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Regents Of The University Of California

100 Medical Plz, Suite 383, 
Los Angeles, CA 
 (37.2 miles away)
310-983-1023
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dana Chase is a Gynecologic Oncologist and an Oncologist in Los Angeles, California. Dr. Chase is highly rated in 18 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy. Dr. Chase is currently accepting new patients in some locations.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cappuccini's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile